Search
Powered By HealthLine
Health Tools
 Acid Reflux Revention
 Info About The Large Intestine
 The Stomach and Small Intestine
 Check Symptoms for Acid Reflux
 Check IBD Symptoms
 The Facts About Infant Intestines
 Quiz: The Digestive System
 Ask A Questions About IBD
 Causes of Acid Reflux
 Ask A Question About Digestion
Featured Conditions
 Acid Reflux
 Acid Reflux
 Inflammatory Bowel Disease
 Diet & Exercise
 Cholesterol
 Diet & Exercise
 Cholesterol
 Inflammatory Bowel Disease
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & Precautions
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Combivent

[ipratropium bromide and albuterol sulfate]

Pregnancy

TERATOGENIC EFFECTS

Pregnancy Category C

Text Continues Below



Ipratropium bromide:

Pregnancy Category B. Oral reproduction studies were performed at doses of 10 mg/ kg in mice, 100 mg/ kg in rats and 125 mg/ kg in rabbits. These doses correspond, in each species, respectively, to approximately 300, 600 and 15, 000 times the maximum recommended human daily inhalation dose on a mg/ m 2 basis. Inhalation reproduction studies were conducted in rats and rabbits at doses of 1.5 and 1.8 mg/ kg/ day (approximately 90 and 210 times the maximum recommended human daily inhalation dose on a mg/ m 2 basis). These studies have demonstrated no evidence of teratogenic effects as a result of ipratropium bromide.

Albuterol:

Pregnancy Category C.

Albuterol has been shown to be teratogenic in mice. A reproduction study in CD-1 mice given albuterol subcutaneously (0. 025, 0.25 and 2. 5 mg/ kg) showed cleft palate formation in 5 of 111 (4. 5%) fetuses at 0. 25 mg/ kg (equivalent to the maximum recommended human daily inhalation dose on a mg/ m 2 basis) and in 10 of 108 (9. 3%) fetuses at 2.5 mg/ kg (approximately 10 times the maximum recommended human daily inhalation dose on a mg/ m 2 basis). None was observed at 0.025 mg/ kg (approximately one-tenth the maximum recommended human daily inhalation dose). Cleft palate also occurred in 22 of 72 (30.5%) fetuses treated with 2.5 mg/ kg isoproterenol (positive control). A reproduction study with oral albuterol in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses at 50 mg/ kg (approximately 1000 times the maximum recommended human daily inhalation dose on a mg/ m 2 basis).

There are, however, no adequate and well-controlled studies of Combivent Inhalation Aerosol, ipratropium bromide or albuterol sulfate, in pregnant women. Because animal reproduction studies are not always predictive of human response, Combivent Inhalation Aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Page:  << Prev | 1 | 2 | 3 | 4 | 5 | Next >>







HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire